Cargando…

Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers

Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of the major manifestations of venous thromboembolism (VTE). It is associated with high mortality and substantial recurrence rates, and its diagnosis may be challenging, especially in patients with respiratory comorb...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkana, Androniki, Papadopoulou, Androniki, Mermiri, Maria, Beltsios, Eleftherios, Chatzis, Dimitrios, Malli, Foteini, Adamou, Antonis, Gourgoulianis, Konstantinos, Mavrovounis, Georgios, Pantazopoulos, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604705/
https://www.ncbi.nlm.nih.gov/pubmed/36294744
http://dx.doi.org/10.3390/jpm12101604
_version_ 1784817881623560192
author Gkana, Androniki
Papadopoulou, Androniki
Mermiri, Maria
Beltsios, Eleftherios
Chatzis, Dimitrios
Malli, Foteini
Adamou, Antonis
Gourgoulianis, Konstantinos
Mavrovounis, Georgios
Pantazopoulos, Ioannis
author_facet Gkana, Androniki
Papadopoulou, Androniki
Mermiri, Maria
Beltsios, Eleftherios
Chatzis, Dimitrios
Malli, Foteini
Adamou, Antonis
Gourgoulianis, Konstantinos
Mavrovounis, Georgios
Pantazopoulos, Ioannis
author_sort Gkana, Androniki
collection PubMed
description Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of the major manifestations of venous thromboembolism (VTE). It is associated with high mortality and substantial recurrence rates, and its diagnosis may be challenging, especially in patients with respiratory comorbidities. Therefore, providing a prompt and accurate diagnosis for PE through developing highly sensitive and specific diagnostic algorithms would be of paramount importance. There is sound evidence supporting the use of biomarkers to enhance the diagnosis and predict the recurrence risk in patients with PE. Therefore, several novel biomarkers, such as factor VIII, Ischemia Modified Albumin, and fibrinogen, as well as several MicroRNAs and microparticles, have been investigated for the diagnosis of this clinical entity. The present review targets to comprehensively present the literature regarding the novel diagnostic biomarkers for PE, as well as to discuss the evidence for their use in daily routine.
format Online
Article
Text
id pubmed-9604705
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96047052022-10-27 Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers Gkana, Androniki Papadopoulou, Androniki Mermiri, Maria Beltsios, Eleftherios Chatzis, Dimitrios Malli, Foteini Adamou, Antonis Gourgoulianis, Konstantinos Mavrovounis, Georgios Pantazopoulos, Ioannis J Pers Med Review Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of the major manifestations of venous thromboembolism (VTE). It is associated with high mortality and substantial recurrence rates, and its diagnosis may be challenging, especially in patients with respiratory comorbidities. Therefore, providing a prompt and accurate diagnosis for PE through developing highly sensitive and specific diagnostic algorithms would be of paramount importance. There is sound evidence supporting the use of biomarkers to enhance the diagnosis and predict the recurrence risk in patients with PE. Therefore, several novel biomarkers, such as factor VIII, Ischemia Modified Albumin, and fibrinogen, as well as several MicroRNAs and microparticles, have been investigated for the diagnosis of this clinical entity. The present review targets to comprehensively present the literature regarding the novel diagnostic biomarkers for PE, as well as to discuss the evidence for their use in daily routine. MDPI 2022-09-29 /pmc/articles/PMC9604705/ /pubmed/36294744 http://dx.doi.org/10.3390/jpm12101604 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gkana, Androniki
Papadopoulou, Androniki
Mermiri, Maria
Beltsios, Eleftherios
Chatzis, Dimitrios
Malli, Foteini
Adamou, Antonis
Gourgoulianis, Konstantinos
Mavrovounis, Georgios
Pantazopoulos, Ioannis
Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers
title Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers
title_full Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers
title_fullStr Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers
title_full_unstemmed Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers
title_short Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers
title_sort contemporary biomarkers in pulmonary embolism diagnosis: moving beyond d-dimers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604705/
https://www.ncbi.nlm.nih.gov/pubmed/36294744
http://dx.doi.org/10.3390/jpm12101604
work_keys_str_mv AT gkanaandroniki contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT papadopoulouandroniki contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT mermirimaria contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT beltsioseleftherios contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT chatzisdimitrios contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT mallifoteini contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT adamouantonis contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT gourgoulianiskonstantinos contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT mavrovounisgeorgios contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers
AT pantazopoulosioannis contemporarybiomarkersinpulmonaryembolismdiagnosismovingbeyondddimers